OneSource Specialty Pharma , formerly known as Stelis Biopharma Limited, has reported its financial results for the first quarter of fiscal year 2026, ending June 30, 2025. The company, which operates primarily in the Contract Development and Manufacturing Organization (CDMO) segment for pharmaceutical products, faced challenges but also announced potential strategic moves. Additionally, the company has recently completed a fresh allotment of equity shares under its employee stock option plan.

Financial Performance

OneSource Specialty Pharma reported a consolidated net loss of ₹1.86 million for Q1 FY26, a significant improvement from the loss of ₹55.47 million in the same quarter last year. The company's revenue from operations increased to ₹3,272.70 million, up from ₹2,922.89 million year-over-year, indicating growth in its core business activities.

On a standalone basis, the company posted a profit of ₹248.15 million, a substantial turnaround from a loss of ₹239.66 million in the previous year's quarter. This improvement in standalone performance suggests stronger operational efficiency within the parent company.

Recent Corporate Actions

In the latest corporate development, OneSource Specialty Pharma's Management Committee approved the allotment of 23,000 equity shares under the OneSource ESOP 2021 plan. The allotment was completed on December 09, 2025, with eligible employees exercising their vested options at a premium of ₹277.00 per share.

Consequent to this allotment, the company's paid-up share capital increased from ₹11,45,62,136 to ₹11,45,85,136, comprising 11,45,85,136 equity shares of ₹1.00 each. The newly allotted shares rank pari passu with existing equity shares in all respects.

Strategic Initiatives and Exceptional Items

The company faced exceptional items worth ₹28.70 million related to legal charges from subsidiary litigation regarding Sputnik vaccine matters during Q1 FY26. Despite these challenges, OneSource Specialty Pharma's Board of Directors has given in-principle approval to evaluate potential acquisitions that could expand the company's capabilities and global reach, including a USFDA-approved sterile fill-finish manufacturing facility in Warsaw, Poland, and an integrated carbapenem facility in Vadodara, India.

Outlook

While OneSource Specialty Pharma faces ongoing challenges, including legal issues related to past vaccine projects, the company's improved revenue, strategic acquisition plans, and continued employee engagement through ESOP allotments indicate a focus on growth and expansion in the CDMO space. The potential acquisitions, particularly of USFDA-approved facilities, could significantly enhance the company's capabilities and market position in the pharmaceutical manufacturing sector.

Onesource Specialty Pharma , a prominent player in the pharmaceutical industry, has announced its decision to withdraw from the upcoming Jefferies Global Healthcare Conference. The event, scheduled for November 18-20, 2025, in London, is a significant platform for healthcare companies to engage with investors and industry peers.

Reason for Withdrawal

The company cited "urgent matters" as the primary reason for their absence from the conference. This unexpected development has raised questions about the nature of these urgent matters and their potential impact on the company's operations.

Impact on Investor Relations

The Jefferies Global Healthcare Conference is known for providing valuable opportunities for companies to:

• Present their business strategies
• Showcase recent developments
• Engage with potential investors

ONESource Specialty Pharma's absence from this event may affect its planned interactions with investors and industry analysts.

Official Communication

ONESource Specialty Pharma officially communicated its decision to withdraw from the conference. The company's Company Secretary and Compliance Officer, Trisha A, signed the official notice, which was submitted to regulatory authorities.

Company Background

ONESource Specialty Pharma Limited, formerly known as Stelis Biopharma Limited, is headquartered in Bengaluru, India. The company operates in the specialty pharmaceutical sector, focusing on developing and manufacturing pharmaceutical products.

Investors and industry observers will likely be watching closely for any further announcements or developments from ONESource Specialty Pharma in the coming days.